EANM Presentations to Showcase New Data and Developments in Telix's Theranostics Pipeline

MELBOURNE, Australia and LIEGE, Belgium, Oct. 10, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its presence at the European Association of Nuclear Medicine (EANM) Annual Congress to be held in Barcelona from 15-19 October, 2022.

Dr. Colin Hayward, Telix Chief Medical Officer said, "Telix is pleased to have such a strong presence at EANM'22, which is being held in-person for the first time since 2019. Our sponsored symposium provides an insight to the advancements in imaging, surgery and patient management for the genitourinary oncology field. The congress program also includes updates on a wide variety of Telix-sponsored and investigator-initiated studies and research collaborations, including preliminary data read outs, notably identifying carbonic anhydrase IX (CAIX) as a therapeutic target beyond renal cancer. The breadth of our innovative theranostic pipeline is demonstrative of our commitment and progress towards advancing nuclear medicine across a range of indications."

EANM presentation details are as follows:

Sponsored Symposium: Shifting Perspectives in Genitourinary Oncology through Nuclear Medicine

• Chairperson: Professor Wolfgang Fendler - Vice Chair, Clinic for Nuclear Medicine, Essen University Hospital, Essen, Germany.
  
  
• PSMA-ligand PET imaging: current status and impact on patient management.

-Professor Wolfgang Fendler.

• Interventional nuclear medicine: focus on radioguided surgery in urology cancers.

-Professor Jochen Walz - Head of the Department of Urology at the Institut Paoli-Calmettes Cancer Centre, Marseille, France.

• Redefining the management of renal cancer patients.

-Doctor Stijn Muselaers - Department of Urology, Radboud University Medical Center, Nijmegen, the Netherlands.

• Establishing radio ligand imaging and therapy in hospital practice.

-Professor Zéna Wimana - Radiopharmacy Manager, Department of Nuclear Medicine, Institut Jules Bordet, Brussels, Belgium.

• Date & Time: Sunday,16 October, 2022, 13:15 - 14:45 CET.

Oral Presentations:

1. Preclinical evaluation of targeted radionuclide therapy combined with immune checkpoint inhibition.
   Top Rated Oral Presentation (TROP).
   Date & Time: Sunday, October 16, 2022, 15:50 – 16:00 CET.
   Presenter: Simone Kleinendorst (Radboud University Medical Centre).
   Presentation Number: OP-170.
   
   
2. ProstACT TARGET: oligometastatic prostate cancer treated by external beam and Theranostics radioligand therapy.
   Top Rated Oral Presentation (TROP).
   Date & Time: Monday, October 17, 2022, 10:55 – 11:05 CET.
   Presenter: Neel Patel (Telix Pharmaceuticals).
   Presentation Number: OP-386.
   
   
3. Preliminary results of a prospective pilot study, assessing imaging performance of 89Zirconium-labelled Girentuximab PET-CT in metastatic triple negative breast cancer patients (OPALESCENCE).
   Top Rated Oral Presentation (TROP).
   Date & Time: Monday, October 17, 2022, 15:40 – 15:50 CET.
   Presenter: Caroline Rousseau (Institut de Cancérologie de l'Ouest).
   Presentation Number: OP-454.
   
   
4. An automated [89Zr]ZrCl4-based platform for radiolabelling of [89Zr]Zr-DFOsq agents on the iPhase MultiSyn module.
   Top Rated Oral Presentation (TROP).
   Date & Time: Tuesday, October 18, 2022, 17:45 – 17:55 CET.
   Presenter: Catherine Fitzgerald (University of Melbourne).
   Presentation Number: OP-741.
   
   
5. PSMA PET/CT detected prostate cancer metastasis in a patient with negative mpMRI and prostate gland biopsy.
   Date & Time: Sunday, October 16, 2022, 09:14 – 09:18 CET.
   Presenter: Luigia Vetrone (University of Bologna).
   Presentation Number: OP-031.

Poster Presentations:

1. Preliminary results of a clinical feasibility study with intravesically instilled 89Zr-labeled Girentuximab in patients with non-muscle-invasive bladder cancer for future alpha-immunotherapy (PERTINENCE).
   Presenter: Caroline Rousseau (Institut de Cancérologie de l'Ouest).
   Presentation Number: EP-172.
2. Clinical translation of the dead cancer cell-targeting antibody chimeric DAB4 (chDAB4) as a theranostic tool for diagnosing cancer treatment responses.
   Presenter: Alex Staudacher (University of Adelaide).
   Presentation Number: EP-103.

Register here for EANM'22: https://eanm22.eanm.org/

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals. Telix is headquartered in Melbourne, Australia with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical-stage products that aims to address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn.

Telix's lead product, gallium-68 (⁶⁸Ga) gozetotide (also known as ⁶⁸Ga PSMA-11) injection, has been approved by the U.S. Food and Drug Administration (FDA),^[1] and by the Australian Therapeutic Goods Administration (TGA).^[2] Telix is also progressing a marketing authorisation application for this investigational candidate in Canada.^[3]

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Corporate Communications and Investor Relations
Email: [email protected]

This announcement has been authorised for release by the disclosure committee of Telix Pharmaceuticals Limited.

Legal Notices

This announcement is not intended as promotion or advertising directed to any healthcare professional or other audience in any country worldwide (including Australia, United States and the United Kingdom). This announcement may include forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments.  Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "outlook", "forecast" and "guidance", or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical studies, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix's product candidates, if or when they have been approved; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the ASX or on our website.

To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future developments or a change in expectations or assumptions.  

The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.

Logo - https://mma.prnewswire.com/media/1775408/Telix_Logo.jpg